• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Recurrent Clostridium difficile diarrhoea.

作者信息

Kyne L, Kelly C P

机构信息

Harvard Medical School, Gerontology and Gastroenterology Divisions, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA.

出版信息

Gut. 2001 Jul;49(1):152-3. doi: 10.1136/gut.49.1.152.

DOI:10.1136/gut.49.1.152
PMID:11413124
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1728368/
Abstract
摘要

相似文献

1
Recurrent Clostridium difficile diarrhoea.复发性艰难梭菌腹泻
Gut. 2001 Jul;49(1):152-3. doi: 10.1136/gut.49.1.152.
2
[The approach to recurrent infections with Clostridium difficile].[艰难梭菌复发性感染的治疗方法]
Harefuah. 2008 Nov;147(11):864-5, 942.
3
Clostridium difficile: an update.艰难梭菌：最新进展
Compr Ther. 2004 Fall-Winter;30(3):134-40. doi: 10.1007/s12019-004-0009-z.
4
Recurrent Clostridium difficile colitis.复发性艰难梭菌结肠炎
Compr Ther. 2004 Fall-Winter;30(3):160-3. doi: 10.1007/s12019-004-0013-3.
5
[Recurrent Clostridium difficile enterocolitis].[复发性艰难梭菌性小肠结肠炎]
Schweiz Med Wochenschr. 2000 Nov 4;130(44):1681-4.
6
[Infections with Clostridium difficile following antibiotic therapy].[抗生素治疗后艰难梭菌感染]
MMW Fortschr Med. 2009 Oct 1;151(40):47-9.
7
Pseudomembranous colitis.
Schweiz Rundsch Med Prax. 1982 Jan 19;71(3):98-106.
8
[Occurrence and treatment of Clostridium difficile-associated diarrhea].
Ugeskr Laeger. 2006 Jun 26;168(26-32):2579; author reply 2579-80.
9
Treatment strategies for C. difficile associated diarrhea.艰难梭菌相关性腹泻的治疗策略。
Acta Gastroenterol Latinoam. 2007 Sep;37(3):183-91.
10
Update on Clostridium difficile infection.艰难梭菌感染的最新情况
Curr Gastroenterol Rep. 2000 Aug;2(4):310-4. doi: 10.1007/s11894-000-0024-x.

引用本文的文献

1
Age-targeted vaccination for reducing Clostridioides difficile infection in England: a coupled mathematical-economic modelling analysis.英格兰针对不同年龄组的疫苗接种以减少艰难梭菌感染：一项数学 - 经济耦合建模分析
BMC Med. 2025 Jul 15;23(1):426. doi: 10.1186/s12916-025-04265-x.
2
Microbiota-mediated protection against antibiotic-resistant pathogens.微生物群介导的对抗抗生素耐药病原体的保护作用。
Genes Immun. 2021 Oct;22(5-6):255-267. doi: 10.1038/s41435-021-00129-5. Epub 2021 May 4.
3
In vivo efficacy of auranofin in a hamster model of Clostridioides difficile infection.金诺芬在仓鼠艰难梭菌感染模型中的体内疗效。
Sci Rep. 2021 Mar 29;11(1):7093. doi: 10.1038/s41598-021-86595-3.
4
Acid Suppression Medications During Hospitalization as a Risk Factor for Recurrence of Clostridioides difficile Infection: Systematic Review and Meta-analysis.住院期间使用抑酸药物与艰难梭菌感染复发的风险因素：系统评价和荟萃分析。
Clin Infect Dis. 2021 Jul 1;73(1):e62-e68. doi: 10.1093/cid/ciaa545.
5
Role of the global regulator Rex in control of NAD -regeneration in Clostridioides (Clostridium) difficile.全局调节子 Rex 在艰难梭菌（梭状芽孢杆菌属）中 NAD 再生控制中的作用。
Mol Microbiol. 2019 Jun;111(6):1671-1688. doi: 10.1111/mmi.14245. Epub 2019 Apr 2.
6
Intravenous immunoglobulin therapy for refractory toxin colitis in chronic kidney disease: case reports and literature review.静脉注射免疫球蛋白治疗慢性肾脏病难治性毒素性结肠炎：病例报告及文献综述
NDT Plus. 2008 Feb;1(1):20-22. doi: 10.1093/ndtplus/sfm008. Epub 2007 Dec 19.
7
Novel risk factors for recurrent Clostridium difficile infection in children.儿童复发性艰难梭菌感染的新危险因素
J Pediatr Gastroenterol Nutr. 2015 Jan;60(1):18-22. doi: 10.1097/MPG.0000000000000553.
8
Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection.非达霉素与万古霉素治疗艰难梭菌感染的成本效益分析
J Antimicrob Chemother. 2014 Nov;69(11):2901-12. doi: 10.1093/jac/dku257. Epub 2014 Aug 5.
9
5-Aminosalicylic Acid Inhibits Acute Clostridium difficile Toxin A-Induced Colitis in Rats.
Int J Inflam. 2014;2014:389621. doi: 10.1155/2014/389621. Epub 2014 Jun 23.
10
Clinical predictors of recurrent Clostridium difficile infection in out-patients.门诊患者复发性艰难梭菌感染的临床预测因素
Aliment Pharmacol Ther. 2014 Sep;40(5):518-22. doi: 10.1111/apt.12864. Epub 2014 Jul 10.

本文引用的文献

1
Prospects for a vaccine for Clostridium difficile.艰难梭菌疫苗的前景。
BioDrugs. 1998 Sep;10(3):173-81. doi: 10.2165/00063030-199810030-00001.
2
Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea.针对毒素A的抗体反应与预防艰难梭菌复发性腹泻之间的关联。
Lancet. 2001 Jan 20;357(9251):189-93. doi: 10.1016/S0140-6736(00)03592-3.
3
Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.艰难梭菌无症状携带与抗毒素A的IgG抗体血清水平
N Engl J Med. 2000 Feb 10;342(6):390-7. doi: 10.1056/NEJM200002103420604.
4
Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee.艰难梭菌相关性腹泻和结肠炎的诊断与管理指南。美国胃肠病学院，实践参数委员会。
Am J Gastroenterol. 1997 May;92(5):739-50.
5
A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease.一项关于布拉氏酵母菌联合标准抗生素治疗艰难梭菌病的随机安慰剂对照试验。
JAMA. 1994;271(24):1913-8.
6
Clostridium difficile colitis.艰难梭菌结肠炎
N Engl J Med. 1994 Jan 27;330(4):257-62. doi: 10.1056/NEJM199401273300406.
7
Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991.
Infect Control Hosp Epidemiol. 1994 Jun;15(6):371-81. doi: 10.1086/646934.
8
Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis.抗生素相关性假膜性结肠炎多次复发患者的治疗方法
Am J Gastroenterol. 1985 Nov;80(11):867-8.
9
Therapy of relapsing Clostridium difficile-associated diarrhea and colitis with the combination of vancomycin and rifampin.万古霉素与利福平联合治疗复发性艰难梭菌相关性腹泻和结肠炎
J Clin Gastroenterol. 1987 Apr;9(2):155-9. doi: 10.1097/00004836-198704000-00009.
10
Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin.静脉注射丙种球蛋白治疗艰难梭菌毒素引起的慢性复发性结肠炎。
J Pediatr. 1991 Apr;118(4 Pt 1):633-7. doi: 10.1016/s0022-3476(05)83393-1.